Abstract Background: Antibody–drug conjugates (ADCs) have transformed solid-tumor therapy and are increasingly benchmarked directly against physician’s-choice chemotherapy. However, kidney adverse events and electrolyte disturbances remain inconsistently captured across trials and are often interpreted without a unified pharmacological framework.
Zikun Wang
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Zikun
Contact Zikun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack